Not every patient is a LASIK candidate. For millions of Americans — those with high prescriptions, thin corneas, or dry eye concerns — the EVO Implantable Collamer Lens (ICL) represents a superior path to clear, glasses-free vision. Yet EVO ICL remains widely underrecognized by consumers, and the quality of surgeons performing the procedure varies considerably.
The EVO ICL Awards program exists to change that.
Lasik Awards evaluates and recognizes the best EVO ICL surgeons practicing in the United States today. Our mission is straightforward: give consumers the confidence to make an informed decision and give outstanding ophthalmologists the recognition they have earned. Whether you are researching vision correction for the first time or actively comparing surgeons, this hub is your authoritative starting point.
EVO ICL has been FDA-approved since 2022 and has been implanted in more than two million eyes worldwide. Clinical outcomes consistently show exceptional visual acuity results and high patient satisfaction — in many studies, surpassing outcomes reported for LASIK in comparable populations. Despite this track record, most consumers have never heard of it. If you are among them, you are about to understand why leading ophthalmologists consider EVO ICL one of the most important advances in elective vision correction in the last two decades.
What Is EVO ICL?
EVO ICL — short for EVO Implantable Collamer Lens — is an additive lens that a surgeon places inside the eye, between the iris and the natural crystalline lens. Unlike LASIK, it does not remove corneal tissue. Instead, it works with your eye’s existing anatomy to correct nearsightedness (myopia), with or without astigmatism.
The lens is made from Collamer, a proprietary biocompatible material developed by STAAR Surgical. Collamer contains a small amount of collagen, which allows it to integrate naturally with the eye’s aqueous humor and remain virtually undetectable by the patient after implantation. It does not cause inflammation, does not touch the natural lens, and does not interfere with the eye’s ability to focus at various distances.
The “EVO” designation refers to the latest generation of the Visian ICL, which includes a small central port — called a KS-Aquaport — that allows fluid to circulate freely through the lens without the need for a peripheral iridotomy. That procedural simplification reduces pre-surgical preparation and improves the patient experience.
For a comprehensive explanation of how the lens works, its FDA approval history, and the science behind Collamer material, see our complete guide to what EVO ICL is.
EVO ICL vs. LASIK: Understanding Your Options
Both LASIK and EVO ICL correct nearsightedness and astigmatism. Both are outpatient procedures. Both produce rapid improvements in vision. But they are fundamentally different technologies, and that difference matters.
LASIK uses a laser to permanently reshape the cornea by removing tissue. Results are generally excellent, but candidacy depends on having sufficient corneal thickness, appropriate corneal curvature, stable refraction, and adequate tear film production. Once the cornea is reshaped, that tissue is gone permanently.
EVO ICL is additive. Nothing is removed from the eye. The lens is placed inside the eye and can be removed or replaced if prescriptions change, if technology improves, or if the patient later becomes a LASIK candidate. For patients who have been told they do not qualify for LASIK, EVO ICL is often the best available alternative — and in some cases, it produces superior outcomes even in patients who would qualify for both procedures.
Key differences worth understanding:
- Dry eye: LASIK severs corneal nerves that regulate tear production, which can cause or worsen dry eye. EVO ICL does not alter the cornea, making it a preferred option for patients with existing dry eye conditions.
- Night vision: Some patients report improved night vision quality with EVO ICL compared to LASIK, due to the preservation of the eye’s natural optics.
- High prescriptions: EVO ICL corrects prescriptions from -3.00 to -20.00 diopters of myopia — a range that extends well beyond what LASIK can safely treat.
- Reversibility: EVO ICL can be removed. LASIK cannot.
Neither procedure is universally superior. The right choice depends on your anatomy, prescription, lifestyle, and preferences. For a detailed head-to-head comparison, visit our EVO ICL vs. LASIK comparison guide.
If you are researching LASIK specifically, explore the LASIK Awards hub, where we recognize America’s top LASIK surgeons and provide the same depth of consumer education.
Who Is a Good Candidate for EVO ICL?
EVO ICL was designed for a specific patient profile, and understanding candidacy requirements is essential before scheduling a consultation.
Ideal Candidates
The best EVO ICL candidates share several characteristics:
- Age: Generally between 21 and 45, with a stable prescription for at least one year
- Myopia: Between -3.00 and -20.00 diopters, with up to -4.00 diopters of astigmatism (with the toric EVO ICL)
- Corneal thickness: Patients with thin corneas who do not qualify for LASIK often qualify for EVO ICL because no corneal tissue is removed
- Anterior chamber depth: The surgeon must verify that sufficient space exists between the cornea and natural lens to safely accommodate the ICL
- Dry eye: Patients with dry eye disease who are not LASIK candidates may be excellent EVO ICL candidates
- Active lifestyle: EVO ICL is particularly popular among athletes and outdoor enthusiasts because the lens is not subject to dislodgement from contact sports or trauma in the same way a reshaped corneal flap can be
Who Is Not a Candidate
EVO ICL is not appropriate for patients with narrow-angle glaucoma, certain types of cataracts, corneal disease such as keratoconus, or those whose anterior chamber measurements fall outside the required parameters. A qualified surgeon will measure and evaluate all relevant factors during a comprehensive pre-operative examination.
For a detailed candidacy checklist and a guide to the questions you should ask at your consultation, see our full EVO ICL candidacy guide.
The EVO ICL Procedure: What to Expect
One of the most common patient concerns is surgical complexity. EVO ICL is a minimally invasive procedure, but it is an intraocular surgery — the surgeon is working inside the eye — and patients deserve a clear, honest account of what the process involves.
Before Surgery
Your surgeon will conduct a comprehensive pre-operative examination that includes:
- Corneal topography and pachymetry (corneal thickness mapping)
- Anterior chamber depth measurement
- Pupil dilation and retinal evaluation
- ICL sizing — the lens must be custom-ordered to fit your eye’s internal dimensions
Because the EVO ICL is custom-manufactured by STAAR Surgical based on your measurements and prescription, there is typically a one- to two-week lead time between your evaluation and your procedure date.
The Day of Surgery
The procedure itself typically takes 20 to 30 minutes per eye. Most surgeons treat both eyes on the same day or within a short interval.
Steps include:
1. Topical anesthetic drops are applied — no injections are required in most cases 2. A small self-sealing incision (approximately 3 millimeters) is made at the corneal limbus 3. A viscoelastic gel is used to protect the eye’s natural structures 4. The EVO ICL is loaded into an injector, introduced through the incision, and unfolded inside the anterior chamber 5. The surgeon positions the lens beneath the iris, using the iris as a natural anchor 6. The viscoelastic is removed, and the incision seals without sutures 7. Antibiotic and anti-inflammatory drops are applied
Most patients report little to no discomfort during the procedure. Mild pressure or light sensitivity may occur immediately afterward.
Immediately After Surgery
Vision improvement is typically immediate. Many patients can see clearly within hours of surgery. You will need a driver to take you home, and you should plan to rest for the remainder of the day. A follow-up examination is typically scheduled for the next morning.
For a step-by-step walkthrough of the complete procedure experience — including what to expect in the days leading up to surgery and what to avoid in recovery — read our detailed EVO ICL procedure guide.
Recovery and Results
EVO ICL recovery is generally faster and more comfortable than patients expect. Because no tissue is removed from the cornea and the incision is small and self-sealing, the eye heals quickly.
Recovery Timeline
- Day 1: Most patients achieve functional vision within hours. A follow-up exam confirms lens positioning and intraocular pressure.
- Days 2–7: Mild light sensitivity and occasional glare or halos around lights are common and typically resolve within the first week.
- Week 2: Most patients return to work and normal daily activities. Driving clearance is given by the surgeon once visual acuity meets the required threshold.
- Month 1: The vast majority of patients have achieved their target visual outcome by 30 days post-operatively.
- Ongoing: Annual eye examinations are recommended to monitor lens position, intraocular pressure, and the health of the natural crystalline lens.
Clinical Outcomes
Published clinical data is consistently strong. FDA approval studies and post-market surveillance have demonstrated:
- More than 99% of patients achieve 20/40 or better uncorrected visual acuity
- More than 93% achieve 20/20 or better
- High satisfaction rates, often exceeding 99% in surgeon-reported series
- Minimal risk of lens-related complications when implanted by a trained, experienced surgeon
Results are highly dependent on surgeon experience and the precision of ICL sizing. This is one of the primary reasons surgeon selection matters — and why the EVO ICL Awards program focuses heavily on outcomes data when evaluating surgeons.
For a complete breakdown of recovery expectations and long-term results, see our EVO ICL recovery and results guide.
Safety and Clinical Evidence
EVO ICL has one of the most thoroughly studied safety profiles in elective ophthalmology. With more than two million implantations worldwide and over 20 years of clinical experience with predecessor Visian ICL technology, the safety record is well-established.
FDA Approval and Clinical Trials
The EVO ICL received FDA approval in March 2022 following a pivotal clinical trial that enrolled 505 eyes across multiple U.S. sites. The study found:
- No serious adverse events related to the device
- No cases of significant loss of best-corrected visual acuity
- High rates of visual accuracy — the percentage of eyes within 0.5 diopters of target correction
- No clinically significant changes in endothelial cell density over three years of follow-up
Endothelial cell health — the integrity of the inner cell layer of the cornea — is a primary safety consideration for any intraocular lens. Long-term studies have confirmed that the EVO ICL design, with its central aquaport facilitating natural fluid circulation, does not cause clinically significant endothelial cell loss when properly sized and implanted.
Surgeon Experience Matters
It is critical to understand that ICL safety outcomes are not uniform across all surgeons. The procedure requires precise lens sizing, careful technique, and experience in managing the unique anatomical considerations of intraocular lens implantation. Surgeons who perform high volumes of EVO ICL procedures consistently demonstrate better outcomes in the peer-reviewed literature.
This is not a procedure to entrust to a surgeon who performs it occasionally. It is one of the most important factors the EVO ICL Awards program evaluates.
For a comprehensive review of the clinical evidence, safety data, and what the long-term studies tell us, see our EVO ICL safety and clinical results guide.
EVO ICL for High Prescriptions and Thin Corneas
One of the most underappreciated strengths of EVO ICL is its ability to serve patients who have been turned away by other vision correction procedures. These patients — often highly myopic, with prescriptions that have constrained their options for years — represent a group for whom EVO ICL is not merely an alternative but frequently the best available procedure.
High Myopia
LASIK safely corrects prescriptions up to approximately -9.00 or -10.00 diopters in most patients, though many surgeons conservatively cap their treatment at lower levels to preserve corneal integrity. EVO ICL is FDA-approved to treat up to -20.00 diopters of myopia.
For a patient with a -14.00 diopter prescription who has been told they are not a LASIK candidate and has worn thick, heavy lenses their entire life, EVO ICL can be transformative.
Thin Corneas
LASIK requires the removal of corneal tissue, which means patients with thin corneas — or corneas that are thin relative to the correction required — may be disqualified. EVO ICL removes nothing from the cornea. A patient with a corneal thickness of 480 microns who cannot safely undergo LASIK may be an excellent EVO ICL candidate, provided the anterior chamber depth and other parameters are appropriate.
Keratoconus Suspects
Patients identified as keratoconus suspects — those with irregular corneal topography that disqualifies them from LASIK due to ectasia risk — are frequently good EVO ICL candidates. The procedure does not alter corneal biomechanics, eliminating the ectasia risk entirely.
For patients in this category, EVO ICL is not a consolation prize. In many respects, it is the superior option. To learn more, see our guide to EVO ICL for high prescriptions and thin corneas.
How We Evaluate EVO ICL Surgeons
The EVO ICL Awards are not an advertising program, a pay-to-play listing service, or a directory built on self-reported credentials. We evaluate surgeons using a rigorous, multi-factor framework developed in consultation with ophthalmology professionals and informed by the peer-reviewed literature on surgical outcomes.
Evaluation Criteria
1. Clinical Training and Credentials We verify board certification through the American Board of Ophthalmology (ABO) and confirm subspecialty fellowship training in refractive or corneal surgery where applicable. Surgeons who have completed STAAR Surgical’s EVO ICL clinical training and have demonstrated procedural competency are given additional weight.
2. Volume and Experience The number of EVO ICL procedures a surgeon has performed is a meaningful proxy for outcomes. We look for surgeons who perform the procedure regularly — not those for whom it is an occasional offering. High-volume centers that specialize in EVO ICL typically produce the strongest results.
3. Outcomes Data Where available, we review outcomes data including uncorrected visual acuity results, rates of re-treatment, patient satisfaction scores, and complication rates. Surgeons who participate in outcomes registries or publish their results are recognized for that transparency.
4. Patient Experience We review patient-reported feedback across multiple verified platforms. We look for consistency, responsiveness, and evidence that the surgeon invests in the consultation and follow-up process — not just the procedure itself.
5. Technology and Equipment Award-recognized surgeons operate in facilities equipped with current diagnostic and surgical technology. This includes advanced biometry, corneal tomography, and the surgical equipment required to perform the procedure safely at the highest level.
6. Commitment to Education Surgeons who educate their patients — through consultations, content, and transparent communication about candidacy, risks, and alternatives — demonstrate a patient-first approach that aligns with the Lasik Awards mission.
For the complete methodology and scoring framework, see how we evaluate EVO ICL surgeons.
Cost and Financing
EVO ICL is a premium elective procedure. It is not covered by standard vision insurance, and the cost is higher than LASIK due to the custom manufacturing of the lens and the complexity of the intraocular surgical technique.
Average Cost Range
In the United States, EVO ICL typically costs between $4,000 and $6,000 per eye, with an average of approximately $4,500 to $5,500 per eye at established centers. The all-in cost for both eyes — including pre-operative evaluation, the procedure, and follow-up care — typically ranges from $8,000 to $12,000.
Cost varies based on:
- Geographic market and practice overhead
- Surgeon experience and reputation
- Facility fees
- Whether the toric version (for astigmatism correction) is used
- The extent of pre- and post-operative care included in the quoted price
Why Cost Should Not Be the Primary Decision Driver
A surgeon offering EVO ICL at significantly below-market prices is a concern, not a bargain. The procedure involves custom manufacturing, specialized training, and exacting technique. Surgeons who compete primarily on price may be cutting corners on evaluation rigor, technology, or follow-up care.
We are direct about this: the cheapest EVO ICL surgeon is rarely the best choice. Prioritize outcomes, credentials, and patient experience. The cost difference between a mediocre result and an excellent one is paid in quality of life, not dollars.
Financing Options
Most EVO ICL centers offer financing through third-party healthcare credit programs such as CareCredit, Alphaeon Credit, or in-house payment plans. Monthly payments for a full bilateral procedure often fall in the range of $200 to $350 per month over 24 to 36 months, depending on credit terms.
Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for EVO ICL, and the procedure qualifies as a medical expense for tax purposes.
For a full breakdown of cost factors, financing options, and how to evaluate price quotes from competing surgeons, see our EVO ICL cost and financing guide.
The Reversibility Advantage
Among all the differentiating features of EVO ICL, reversibility is perhaps the most underappreciated — and the most meaningful for many patients.
LASIK permanently alters the cornea. Once the tissue is removed, it cannot be restored. This is not a criticism of LASIK — for the right patient, permanent correction is exactly what is wanted. But for some patients, the irreversibility of LASIK is a genuine concern.
EVO ICL is different. If a patient’s prescription changes significantly, the lens can be removed and replaced with a lens of a different power. If the patient later develops a cataract and requires cataract surgery, the ICL can be removed to allow for standard cataract lens implantation. If a superior vision correction technology becomes available in the future, the EVO ICL is not an obstacle to accessing it.
This reversibility is also psychologically meaningful. Many patients who have been hesitant about permanent corneal surgery find that the ability to reverse or update the procedure gives them the confidence to move forward.
It is important to be precise: reversibility does not mean the procedure is trivial to reverse or that patients should expect to frequently revise their lens. Removal or exchange is still an intraocular surgery performed under appropriate clinical conditions. But the option exists — and with LASIK, it does not.
To understand the full clinical and practical implications of EVO ICL reversibility, read our guide to EVO ICL reversibility.
Surgeon Credentials: What to Look For
Selecting a surgeon is the single most important decision you will make in this process. The procedure matters. The technology matters. But the surgeon’s skill, training, judgment, and character matter more than any other factor.
Board Certification
Every EVO ICL surgeon you consider should be certified by the American Board of Ophthalmology. Board certification requires completion of an accredited residency program, passage of written and oral examinations, and ongoing continuing medical education. It is the baseline standard — not a differentiator, but a requirement.
Fellowship Training
Board certification establishes foundational competency. Fellowship training in corneal and refractive surgery goes further, providing specialized experience in the full range of vision correction procedures. Surgeons who have completed refractive surgery fellowships have been mentored by recognized experts and have performed procedures under supervision before operating independently.
EVO ICL-Specific Training
STAAR Surgical requires physicians to complete training before implanting the EVO ICL. Look for surgeons who have completed this training and who regularly attend continuing education programs in refractive surgery to stay current on technique and outcomes.
Consultation Quality
A surgeon who recommends EVO ICL to every patient regardless of candidacy is not exercising clinical judgment. A surgeon who takes the time to explain why you are or are not a candidate, what your options are, and what outcomes you should realistically expect — that is a surgeon who prioritizes your long-term outcome over a single procedure fee.
For a complete guide to evaluating surgeon credentials, including the questions to ask at your consultation and the red flags that should concern you, see our EVO ICL surgeon credentials guide. You should also consult our comprehensive guide to choosing an eye surgeon, which covers the evaluation framework applicable across all vision correction procedures.
EVO ICL for Active Lifestyles
For athletes, outdoor enthusiasts, military personnel, law enforcement officers, and others who lead physically demanding lives, vision correction is not just about convenience — it is about performance and safety.
Contact Lens Limitations
Contact lenses are problematic for many active patients. They dry out during extended outdoor activity. They collect dust, debris, and sweat. They present infection risks in aquatic environments. They can be dislodged during contact sports. And they require ongoing cost and maintenance that compounds over years.
LASIK has been an excellent solution for many in this group, but the creation of a corneal flap during traditional LASIK introduces a structural consideration: the flap can, under extreme trauma, be disturbed. SMILE and advanced surface ablation procedures have different structural profiles, but they still involve permanent corneal alteration.
EVO ICL does not create a corneal flap, does not remove tissue, and does not structurally weaken the cornea. Once healed — typically within two to four weeks — patients engage in contact sports, swimming, skiing, and other high-impact activities without restriction related to the procedure.
Military and Law Enforcement
U.S. military branches have specific refractive surgery policies, and some have approved EVO ICL for certain personnel. Patients in these professions should consult with their service’s medical authority regarding eligibility, but EVO ICL is an active area of interest for occupational health in these communities given its corneal-sparing profile.
Diving and Water Sports
Because EVO ICL does not involve a corneal flap and the eye heals through a small self-sealing incision, the restrictions on water exposure are typically shorter than those following LASIK. Your surgeon will specify the timeline for returning to swimming and diving.
To learn more about how EVO ICL serves active patients and what precautions apply during recovery, see our guide to EVO ICL for active lifestyles.
Built-In UV Protection
Every EVO ICL contains a built-in ultraviolet light filter. The Collamer material used in the lens blocks UV-A and UV-B radiation, providing an additional layer of protection for the natural crystalline lens and retina.
This feature is particularly meaningful for:
- Patients with high myopia, who already carry elevated risk for retinal complications and who benefit from every available protective measure
- Outdoor athletes and workers with significant UV exposure
- Patients in high-altitude or high-latitude environments where UV intensity is greater
- Younger patients whose cumulative UV exposure over decades is a meaningful long-term health consideration
It is important to clarify that EVO ICL’s UV protection does not replace sunglasses. UV protection sunglasses remain important for protecting the front surface of the eye and the eyelids. But the internal UV filtration provides a layer of protection that neither LASIK nor glasses nor contact lenses can replicate.
For more information on this feature and its clinical significance, see our guide to EVO ICL UV protection.
Frequently Asked Questions About EVO ICL
The following questions represent the most common points of confusion and concern among patients researching EVO ICL. Each links to a dedicated answer page with full clinical detail.
Is EVO ICL painful? Most patients experience minimal discomfort during the procedure due to topical anesthetic drops, and mild soreness or light sensitivity in the first 24 hours. The procedure is not described as painful by the overwhelming majority of patients. Read: Is EVO ICL painful?
How long does EVO ICL last? The EVO ICL is designed to be a permanent long-term solution. It does not degrade or need routine replacement. However, as patients age and develop cataracts, the ICL may be removed to allow for standard cataract surgery. Read: How long does EVO ICL last?
Can I feel the EVO ICL in my eye? No. The lens is positioned behind the iris, out of contact with the cornea and eyelid. Patients do not feel the lens after surgery. Read: Can you feel the EVO ICL lens?
What is the difference between EVO ICL and standard Visian ICL? The EVO ICL is the current-generation design, featuring a central KS-Aquaport that eliminates the need for a preparatory laser procedure (peripheral iridotomy) required with earlier Visian ICL models. Read: EVO ICL vs. Visian ICL — what’s the difference?
Am I too old for EVO ICL? EVO ICL is FDA-approved for patients between 21 and 45 years of age, though some surgeons treat patients outside this range on a case-by-case basis. Patients over 45 may be developing early presbyopia, which affects the treatment decision. Read: Am I too old for EVO ICL?
What are the risks of EVO ICL? All surgical procedures carry risk. EVO ICL risks include elevated intraocular pressure, cataract formation (typically associated with improper sizing), retinal detachment (rare), and halos or glare that may persist beyond the initial healing period. Your surgeon should discuss all risks during consultation. Read: What are the risks of EVO ICL?
How do I find the best EVO ICL surgeon near me? Start with board-certified ophthalmologists who have fellowship training in refractive surgery and who perform EVO ICL regularly. Use the EVO ICL Awards directory to find recognized surgeons in your region. Read: How to find the best EVO ICL surgeon near me
Does insurance cover EVO ICL? EVO ICL is an elective refractive procedure and is not covered by standard health or vision insurance. HSAs and FSAs can be applied, and most centers offer financing options. Read: Does insurance cover EVO ICL?
Can EVO ICL correct astigmatism? Yes. The toric EVO ICL corrects up to -4.00 diopters of astigmatism in addition to myopia correction. Read: Does EVO ICL correct astigmatism?
What happens if my prescription changes after EVO ICL? The lens can be exchanged for a different power if prescription changes are significant. In many cases, minor residual prescription is managed with glasses or contact lenses without requiring lens exchange. Read: What happens if my prescription changes after EVO ICL?
Exploring Other Vision Correction Options
EVO ICL is an excellent procedure for the right patient, but it is not the only option worth understanding. Consumers making decisions about vision correction deserve a complete picture.
LASIK
LASIK remains the most widely performed elective vision correction procedure in the United States and is appropriate for a broad range of patients with myopia, hyperopia, and astigmatism who meet candidacy criteria. If you are a LASIK candidate and are researching top surgeons, the LASIK Awards hub recognizes America’s best LASIK surgeons with the same rigor we apply to EVO ICL.
PRK and Advanced Surface Ablation
Photorefractive keratectomy (PRK) and its variants — LASEK and TransPRK — achieve similar results to LASIK through surface laser treatment without creating a corneal flap. PRK is often recommended for patients with thin corneas, dry eyes, or occupations with elevated trauma risk (such as military or contact sports). Recovery takes longer than LASIK, but outcomes are equivalent for most patients.
Choosing the Right Procedure
The most important step any patient can take is consulting with a surgeon who is qualified to offer multiple procedures and who will recommend the one best suited to your specific anatomy and goals — rather than the one they happen to perform most often. For a framework for evaluating your options and your surgeon, see our complete guide to choosing an eye surgeon.
Conclusion: Finding an Award-Winning EVO ICL Surgeon
EVO ICL is one of the most significant advances in elective vision correction of the last two decades. For patients who have been told they are not LASIK candidates, it is frequently the answer they have been looking for. For patients who qualify for both procedures, it deserves serious consideration — particularly for those concerned about dry eye, those with high prescriptions, or those for whom the permanence of corneal surgery gives pause.
The procedure’s outcomes are well-documented. The technology is mature and FDA-approved. The clinical evidence is strong.
What varies — and what matters enormously — is surgeon quality.
The EVO ICL Awards program exists because surgeon selection is the variable most within a patient’s control. Our recognition is based on training, volume, outcomes, patient experience, and commitment to clinical excellence. Surgeons who earn EVO ICL Awards recognition have met a standard that the broader directory of practitioners has not.
If you are beginning your search, use the resources throughout this hub. Understand the procedure. Learn the candidacy criteria. Study the clinical evidence. And when you are ready to identify qualified surgeons in your area, the EVO ICL Awards directory is your starting point.
Your vision is worth the research.
*The EVO ICL Awards program is produced by Lasik Awards, an independent consumer education and surgeon recognition platform. We do not accept payment from surgeons for inclusion in award recognition lists. Our evaluation process is described in full at how we evaluate EVO ICL surgeons.*